A randomized, double-blind, placebo- controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants

Jacob V. Aranda, Ronald Clyman, Blair Cox, Bart Van Overmeire, Paul Wozniak, Ilene Sosenko, Waldemar A. Carlo, Robert M. Ward, Robert Shalwitz, Geraldine Baggs, Anand Seth, Laszlo Darko

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

A multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of intravenous (IV) ibuprofen (L-lysine) for the early closure of nonsymptomatic patent ductus arteriosus (PDA) within 72 hours of birth in extremely low-birth-weight (ELBW) infants with evidence of ductal shunting by echo- cardiogram. Eleven sites enrolled 136 infants with nonsymptomatic early PDA (gestational age < 30 weeks; body weight 500 to 1000 g) to receive a 3-day course (10 mg/kg, 5 mg/kg, and 5 mg/kg) of IV ibuprofen (n = 68) or placebo (n = 68). Cardiac echocardiogram was performed on study days 1 and 14, and with rescue. Infants were followed to 36 weeks postconceptional age. Patient demographics, mean (standard deviation), were similar between ibuprofen and placebo: birth weight: 798.5 g (128.7) versus 797.3 g (132.8); gestational age: 26.1 weeks (1.3) versus 26.2 weeks (1.4); and age at first dose: 1.5 days (0.7). The intent-to-treat analysis of the primary endpoint, subjects rescued, died, or dropped through study day 14, was 21/68 (30.9%) with ibuprofen and 36/68 (52.9%) for placebo (p = 0.005). Death, intraventricular hemorrhage, necrotizing enterocolitis, daily fluid intake/output, liver function, bronchopulmonary dysplasia, and retinopathy of prematurity did not differ. A trend toward decreased periventricular leukomalacia by ibuprofen was noted. IV ibuprofen was effective and safe in the early closure of PDA in preterm neonates.

Original languageEnglish
Pages (from-to)235-246
Number of pages12
JournalAmerican Journal of Perinatology
Volume26
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Extremely Low Birth Weight Infant
Patent Ductus Arteriosus
Ibuprofen
Lysine
Placebos
Parturition
Gestational Age
Periventricular Leukomalacia
Bronchopulmonary Dysplasia
Retinopathy of Prematurity
Necrotizing Enterocolitis
Birth Weight
Randomized Controlled Trials
Body Weight
Demography
Newborn Infant
Hemorrhage
Safety
Liver

Keywords

  • Cyclooxygenase inhibitors
  • Ibuprofen
  • Patent ductus arteriosus
  • Premature newborn
  • Randomized clinical trial

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

A randomized, double-blind, placebo- controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. / Aranda, Jacob V.; Clyman, Ronald; Cox, Blair; Van Overmeire, Bart; Wozniak, Paul; Sosenko, Ilene; Carlo, Waldemar A.; Ward, Robert M.; Shalwitz, Robert; Baggs, Geraldine; Seth, Anand; Darko, Laszlo.

In: American Journal of Perinatology, Vol. 26, No. 3, 01.03.2009, p. 235-246.

Research output: Contribution to journalArticle

Aranda, Jacob V. ; Clyman, Ronald ; Cox, Blair ; Van Overmeire, Bart ; Wozniak, Paul ; Sosenko, Ilene ; Carlo, Waldemar A. ; Ward, Robert M. ; Shalwitz, Robert ; Baggs, Geraldine ; Seth, Anand ; Darko, Laszlo. / A randomized, double-blind, placebo- controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. In: American Journal of Perinatology. 2009 ; Vol. 26, No. 3. pp. 235-246.
@article{3d9fa75af0ce490d91db8cb6887b42b8,
title = "A randomized, double-blind, placebo- controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants",
abstract = "A multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of intravenous (IV) ibuprofen (L-lysine) for the early closure of nonsymptomatic patent ductus arteriosus (PDA) within 72 hours of birth in extremely low-birth-weight (ELBW) infants with evidence of ductal shunting by echo- cardiogram. Eleven sites enrolled 136 infants with nonsymptomatic early PDA (gestational age < 30 weeks; body weight 500 to 1000 g) to receive a 3-day course (10 mg/kg, 5 mg/kg, and 5 mg/kg) of IV ibuprofen (n = 68) or placebo (n = 68). Cardiac echocardiogram was performed on study days 1 and 14, and with rescue. Infants were followed to 36 weeks postconceptional age. Patient demographics, mean (standard deviation), were similar between ibuprofen and placebo: birth weight: 798.5 g (128.7) versus 797.3 g (132.8); gestational age: 26.1 weeks (1.3) versus 26.2 weeks (1.4); and age at first dose: 1.5 days (0.7). The intent-to-treat analysis of the primary endpoint, subjects rescued, died, or dropped through study day 14, was 21/68 (30.9{\%}) with ibuprofen and 36/68 (52.9{\%}) for placebo (p = 0.005). Death, intraventricular hemorrhage, necrotizing enterocolitis, daily fluid intake/output, liver function, bronchopulmonary dysplasia, and retinopathy of prematurity did not differ. A trend toward decreased periventricular leukomalacia by ibuprofen was noted. IV ibuprofen was effective and safe in the early closure of PDA in preterm neonates.",
keywords = "Cyclooxygenase inhibitors, Ibuprofen, Patent ductus arteriosus, Premature newborn, Randomized clinical trial",
author = "Aranda, {Jacob V.} and Ronald Clyman and Blair Cox and {Van Overmeire}, Bart and Paul Wozniak and Ilene Sosenko and Carlo, {Waldemar A.} and Ward, {Robert M.} and Robert Shalwitz and Geraldine Baggs and Anand Seth and Laszlo Darko",
year = "2009",
month = "3",
day = "1",
doi = "10.1055/s-0028-1103515",
language = "English",
volume = "26",
pages = "235--246",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - A randomized, double-blind, placebo- controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants

AU - Aranda, Jacob V.

AU - Clyman, Ronald

AU - Cox, Blair

AU - Van Overmeire, Bart

AU - Wozniak, Paul

AU - Sosenko, Ilene

AU - Carlo, Waldemar A.

AU - Ward, Robert M.

AU - Shalwitz, Robert

AU - Baggs, Geraldine

AU - Seth, Anand

AU - Darko, Laszlo

PY - 2009/3/1

Y1 - 2009/3/1

N2 - A multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of intravenous (IV) ibuprofen (L-lysine) for the early closure of nonsymptomatic patent ductus arteriosus (PDA) within 72 hours of birth in extremely low-birth-weight (ELBW) infants with evidence of ductal shunting by echo- cardiogram. Eleven sites enrolled 136 infants with nonsymptomatic early PDA (gestational age < 30 weeks; body weight 500 to 1000 g) to receive a 3-day course (10 mg/kg, 5 mg/kg, and 5 mg/kg) of IV ibuprofen (n = 68) or placebo (n = 68). Cardiac echocardiogram was performed on study days 1 and 14, and with rescue. Infants were followed to 36 weeks postconceptional age. Patient demographics, mean (standard deviation), were similar between ibuprofen and placebo: birth weight: 798.5 g (128.7) versus 797.3 g (132.8); gestational age: 26.1 weeks (1.3) versus 26.2 weeks (1.4); and age at first dose: 1.5 days (0.7). The intent-to-treat analysis of the primary endpoint, subjects rescued, died, or dropped through study day 14, was 21/68 (30.9%) with ibuprofen and 36/68 (52.9%) for placebo (p = 0.005). Death, intraventricular hemorrhage, necrotizing enterocolitis, daily fluid intake/output, liver function, bronchopulmonary dysplasia, and retinopathy of prematurity did not differ. A trend toward decreased periventricular leukomalacia by ibuprofen was noted. IV ibuprofen was effective and safe in the early closure of PDA in preterm neonates.

AB - A multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of intravenous (IV) ibuprofen (L-lysine) for the early closure of nonsymptomatic patent ductus arteriosus (PDA) within 72 hours of birth in extremely low-birth-weight (ELBW) infants with evidence of ductal shunting by echo- cardiogram. Eleven sites enrolled 136 infants with nonsymptomatic early PDA (gestational age < 30 weeks; body weight 500 to 1000 g) to receive a 3-day course (10 mg/kg, 5 mg/kg, and 5 mg/kg) of IV ibuprofen (n = 68) or placebo (n = 68). Cardiac echocardiogram was performed on study days 1 and 14, and with rescue. Infants were followed to 36 weeks postconceptional age. Patient demographics, mean (standard deviation), were similar between ibuprofen and placebo: birth weight: 798.5 g (128.7) versus 797.3 g (132.8); gestational age: 26.1 weeks (1.3) versus 26.2 weeks (1.4); and age at first dose: 1.5 days (0.7). The intent-to-treat analysis of the primary endpoint, subjects rescued, died, or dropped through study day 14, was 21/68 (30.9%) with ibuprofen and 36/68 (52.9%) for placebo (p = 0.005). Death, intraventricular hemorrhage, necrotizing enterocolitis, daily fluid intake/output, liver function, bronchopulmonary dysplasia, and retinopathy of prematurity did not differ. A trend toward decreased periventricular leukomalacia by ibuprofen was noted. IV ibuprofen was effective and safe in the early closure of PDA in preterm neonates.

KW - Cyclooxygenase inhibitors

KW - Ibuprofen

KW - Patent ductus arteriosus

KW - Premature newborn

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=61449212974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449212974&partnerID=8YFLogxK

U2 - 10.1055/s-0028-1103515

DO - 10.1055/s-0028-1103515

M3 - Article

C2 - 19067286

AN - SCOPUS:61449212974

VL - 26

SP - 235

EP - 246

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 3

ER -